# Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease

> **NCT07682896** · PHASE2 · RECRUITING · sponsor: **Yarrow Bioscience, Inc.** · enrollment: 232 (estimated)

## Conditions studied

- Graves' Disease

## Interventions

- **DRUG:** Experimental: YB-101
- **DRUG:** Placebo YB-101

## Key facts

- **NCT ID:** NCT07682896
- **Lead sponsor:** Yarrow Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-10
- **Primary completion:** 2027-12
- **Final completion:** 2029-09
- **Target enrollment:** 232 (ESTIMATED)
- **Last updated:** 2026-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07682896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07682896, "Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07682896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*